Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) have received a consensus recommendation of “Hold” from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.89.
A number of research analysts recently commented on ALDR shares. Mizuho reiterated a “hold” rating and set a $15.00 price objective on shares of Alder Biopharmaceuticals in a research note on Friday, May 3rd. Zacks Investment Research lowered shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 29th. Credit Suisse Group restated a “neutral” rating on shares of Alder Biopharmaceuticals in a report on Wednesday, July 10th. Cantor Fitzgerald restated a “hold” rating and set a $14.00 target price on shares of Alder Biopharmaceuticals in a report on Thursday, May 2nd. Finally, BidaskClub cut shares of Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday.
A number of large investors have recently modified their holdings of ALDR. Diamond Hill Capital Management Inc. bought a new stake in Alder Biopharmaceuticals during the second quarter worth approximately $126,000. Fulcrum Capital LLC bought a new stake in Alder Biopharmaceuticals during the second quarter worth approximately $127,000. Empire Life Investments Inc. bought a new stake in Alder Biopharmaceuticals during the first quarter worth approximately $130,000. Stifel Financial Corp bought a new stake in Alder Biopharmaceuticals during the fourth quarter worth approximately $154,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in Alder Biopharmaceuticals in the 2nd quarter worth approximately $167,000.
Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by ($0.47). As a group, sell-side analysts predict that Alder Biopharmaceuticals will post -4.43 EPS for the current fiscal year.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.